DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Stomach Cancer

Interventions: Drug: Bevacizumab
Drug: Docetaxel
Drug: Cisplatin
Drug: Irinotecan

First Posted Date: 2006-11-01

Last Posted Date: 2017-08-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 38

Registration Number: NCT00394433

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Rituximab for Prevention of Chronic GVHD

Phase 1

Completed

Conditions: Hematological Malignancies

First Posted Date: 2006-09-22

Last Posted Date: 2014-03-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 65

Registration Number: NCT00379587

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Lenalidomide
Drug: dexamethasone

First Posted Date: 2006-09-19

Last Posted Date: 2025-02-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 68

Registration Number: NCT00378105

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2006-09-19

Last Posted Date: 2016-11-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 65

Registration Number: NCT00378209

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Biological: peripheral blood lymphocyte therapy
Drug: fludarabine phosphate
Drug: methylprednisolone
Drug: thiotepa
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: in vitro-treated peripheral blood stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2006-09-15

Last Posted Date: 2019-07-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00376480

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 3 locations

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: Bortezomib (Velcade)
Drug: Tacrolimus
Drug: Methotrexate
Procedure: blood stem cell transplantation

First Posted Date: 2006-08-29

Last Posted Date: 2013-07-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT00369226

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Ph II CHOP+Velcade in Mediastinal LBCL

Phase 2

Terminated

Conditions: Non-Hodgkin's Lymphoma

First Posted Date: 2006-08-08

Last Posted Date: 2012-12-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT00361621

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Trial of PTK787/ZK 222584 Plus Paclitaxel

Phase 1

Terminated

Conditions: Metastatic Non-hematologic Malignancies

Interventions: Drug: PTK787/ZK 222584
Drug: paclitaxel

First Posted Date: 2006-07-31

Last Posted Date: 2022-04-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 7

Registration Number: NCT00358163

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Phase 2

Completed

Conditions: Neuroblastoma
Unspecified Childhood Solid Tumor, Protocol Specific
Lymphoma
Central Nervous System Tumor, Pediatric
Leukemia
Sarcoma

Interventions: Drug: celecoxib
Drug: cyclophosphamide
Drug: etoposide
Drug: fenofibrate
Drug: thalidomide

First Posted Date: 2006-07-27

Last Posted Date: 2014-10-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 101

Registration Number: NCT00357500

Locations: 🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸
St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

and more 7 locations

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

Not Applicable

Completed

Conditions: Hematologic Malignancies

First Posted Date: 2006-07-21

Last Posted Date: 2009-03-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 31

Registration Number: NCT00355407

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy